Drugs / TL-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07526519 | Apr 2026 → Apr 2027 expected | — | TrueLab Biopharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TL-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07526519 ↗ |
| Route | Intravenous | “Intravenously administered” NCT07526519 ↗ |